Cidara Therapeutics (CDTX) Competitors $19.18 -0.82 (-4.10%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. GYRE, DAWN, AVXL, PHVS, XERS, NTLA, EOLS, AVDL, CRON, and PRAXShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Anavex Life Sciences (AVXL), Pharvaris (PHVS), Xeris Biopharma (XERS), Intellia Therapeutics (NTLA), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Gyre Therapeutics Day One Biopharmaceuticals Anavex Life Sciences Pharvaris Xeris Biopharma Intellia Therapeutics Evolus Avadel Pharmaceuticals Cronos Group Praxis Precision Medicines Gyre Therapeutics (NASDAQ:GYRE) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has better earnings and valuation, GYRE or CDTX? Cidara Therapeutics has lower revenue, but higher earnings than Gyre Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M7.03-$92.93M$0.05158.80Cidara Therapeutics$1.28M164.77-$22.93M-$30.09-0.64 Does the media favor GYRE or CDTX? In the previous week, Cidara Therapeutics had 2 more articles in the media than Gyre Therapeutics. MarketBeat recorded 6 mentions for Cidara Therapeutics and 4 mentions for Gyre Therapeutics. Cidara Therapeutics' average media sentiment score of 0.59 beat Gyre Therapeutics' score of 0.28 indicating that Cidara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cidara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GYRE or CDTX more profitable? Gyre Therapeutics has a net margin of -84.57% compared to Cidara Therapeutics' net margin of -289.05%. Cidara Therapeutics' return on equity of -69.64% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% Cidara Therapeutics -289.05%-69.64%-33.73% Does the MarketBeat Community favor GYRE or CDTX? Cidara Therapeutics received 455 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 70.26% of users gave Cidara Therapeutics an outperform vote. CompanyUnderperformOutperformGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesCidara TherapeuticsOutperform Votes45670.26% Underperform Votes19329.74% Which has more risk & volatility, GYRE or CDTX? Gyre Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Do analysts prefer GYRE or CDTX? Cidara Therapeutics has a consensus target price of $39.14, suggesting a potential upside of 104.08%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cidara Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do insiders & institutionals believe in GYRE or CDTX? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryCidara Therapeutics beats Gyre Therapeutics on 12 of the 19 factors compared between the two stocks. Remove Ads Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.08M$2.84B$5.29B$7.36BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.7530.3521.6917.68Price / Sales164.77433.43371.6292.88Price / CashN/A168.6838.1534.64Price / Book-10.543.416.373.94Net Income-$22.93M-$72.06M$3.20B$247.45M7 Day Performance9.79%0.80%1.67%0.48%1 Month Performance-13.02%-18.85%-9.49%-7.08%1 Year Performance31.37%-30.49%9.59%-0.35% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.101 of 5 stars$19.18-4.1%$39.14+104.1%+21.3%$210.08M$1.28M-0.7590Analyst UpgradeShort Interest ↑GYREGyre Therapeutics0.1318 of 5 stars$7.62+10.1%N/A-49.0%$713.32M$105.76M152.4040Short Interest ↑Gap DownHigh Trading VolumeDAWNDay One Biopharmaceuticals2.4611 of 5 stars$7.02-2.8%$32.29+359.9%-48.1%$711.51M$131.16M-6.8260AVXLAnavex Life Sciences3.4237 of 5 stars$8.33+1.7%$44.00+428.2%+115.6%$708.58MN/A-15.1540Positive NewsPHVSPharvaris1.407 of 5 stars$13.21-7.5%$40.50+206.6%-30.8%$690.75MN/A-4.7230XERSXeris Biopharma4.2971 of 5 stars$4.41flat$6.10+38.3%+136.8%$678.88M$203.07M-9.80290Short Interest ↑News CoverageHigh Trading VolumeNTLAIntellia Therapeutics4.3213 of 5 stars$6.54-1.4%$37.56+474.2%-67.9%$677.00M$57.88M-1.20600Gap DownHigh Trading VolumeEOLSEvolus3.5085 of 5 stars$10.24-4.2%$24.67+140.9%-14.0%$651.13M$266.27M-11.25170Analyst RevisionGap DownAVDLAvadel Pharmaceuticals2.4536 of 5 stars$6.69-1.6%$19.88+197.1%N/A$646.45M$169.12M-8.4770Analyst RevisionNews CoverageGap DownCRONCronos Group1.5818 of 5 stars$1.68-1.8%$3.00+78.6%-29.5%$642.65M$117.62M-12.92450PRAXPraxis Precision Medicines2.9139 of 5 stars$31.53-3.4%$123.33+291.2%-44.4%$635.74M$8.55M-3.06110News CoverageGap Down Remove Ads Related Companies and Tools Related Companies Gyre Therapeutics Competitors Day One Biopharmaceuticals Competitors Anavex Life Sciences Competitors Pharvaris Competitors Xeris Biopharma Competitors Intellia Therapeutics Competitors Evolus Competitors Avadel Pharmaceuticals Competitors Cronos Group Competitors Praxis Precision Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDTX Stock Free CDTX Stock Alerts